抗体

小鼠抗人类IFN-g

MBS670028

0.5毫克

270美元

单克隆

小鼠

未共轭

A35

抗体

小鼠抗人类IFN-g

IFN-丙

Interferon-?, gIFN, IFNG, immune interferon, IIF, type II interferon, T interferon, T cell interferon, mitogen induced interferon, pH2-labile interferon, macrophage-activating factor, MAF

interferon gamma; Interferon gamma; interferon gamma; IFN-gamma; immune interferon; OTTHUMP00000240111; interferon, gamma; Immune interferon

IFNG;IFNG;IFG;IFI

IFNG_HUMAN

单克隆

Mouse IgG1 kappa

A35

小鼠

人类

166

Human Interferon- gamma (IFN- gamma)1-2 This is a neutralizing antibody. A35 monoclonal antibody has been used for epitope mapping of human IFN- gamma 1. The A35 antibody does not bind to denatured IFN- gamma 1.

纯化(UNLB)抗体

The purified (UNLB) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of 100 mM borate buffered saline, pH 8.2. No preservatives or amine-containing buffer salts added. Store at 2- 8 degree C.

酶联免疫吸附测定

Research Application(s): ELISA Capture: A35 monoclonal antibody is useful as a capture antibody3 in a sandwich ELISA for quantifying human IFN- gamma protein levels.1,2 Purified A35 antibody should be paired with biotinylated B27 antibody as the detection antibody, with purified recombinant human IFN- gamma as the standard. Since applications vary, each investigator should determine the optimal concentration appropriate for individual applications. ELISA: Purified (UNLB) antibody

Immunogen: E. coli-expressed recombinant human IFN- gamma

Characterization: To ensure acceptable performance, each batch of product is tested in a sandwich ELISA to conform to characteristics of a standard reference reagent.

1. Favre, C., J. Wijdenes, H. Cabrillat, O. Djossou, J. Banchereau, and J.E. de Vries. 1989. Epitope mapping of recombinant human gamma interferon using monoclonal antibodies. Molec. Immunol. 26:17-25. 2. Abrams, J.S., M.-G. Roncarolo, H. Yssel, U. Andersson, G.J. Gleich, and J.E., Silver. 1992. Strategies of anti-cytokine monoclonal antibody development: Immunoassay of IL-10 and IL-5 in clinical samples. Immunol. Rev. 127:5-24. 3. Paliard, X., De Wall Malefijt, R., Yssel, H., Blanchard, D., Chretien, I., Abrams, J., de Vries, J., and Spits, H. 1988. Simultaneous production of IL-2, Il-4, and IFN- gamma by activated Human CD4+ and CD8+ T cell clones. J. Immunol. 141:849-855.

56786138

NP_000610.2

NM_000619.2

P01579

19,348 Da

ATF-2 Transcription Factor Network Pathway (138006); African Trypanosomiasis Pathway (194384); African Trypanosomiasis Pathway (194323); Allograft Rejection Pathway (83123); Allograft Rejection Pathway (535); Amoebiasis Pathway (167324); Amoebiasis Pathway (167191); Antigen Processing And Presentation Pathway (83074); Antigen Processing And Presentation Pathway (485); Calcineurin-regulated NFAT-dependent Transcription In Lymphocytes Pathway (137993)

This gene encodes a member of the type II interferon family. The protein encoded is a soluble cytokine with antiviral, immunoregulatory and anti-tumor properties and is a potent activator of macrophages. Mutations in this gene are associated with aplastic anemia.

Function: Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons. Subunit structure: Homodimer. Subcellular location: Secreted. Tissue specificity: Released primarily from activated T lymphocytes. Post-translational modification: Proteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161. Involvement in disease: In Caucasians, genetic variation in IFNG is associated with the risk of aplastic anemia (AA) [. MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis. Pharmaceutical use: Available under the name Actimmune (Genentech). Used for reducing the frequency and severity of serious infections associated with chronic granulomatous disease (CGD). Sequence similarities: Belongs to the type II (or gamma) interferon family.

0.5毫克

270美元